- South Korea
- /
- Pharma
- /
- KOSDAQ:A216080
JETEMA (KOSDAQ:216080) adds ₩28b to market cap in the past 7 days, though investors from five years ago are still down 34%
This week we saw the JETEMA, Co., Ltd. (KOSDAQ:216080) share price climb by 14%. But if you look at the last five years the returns have not been good. In fact, the share price is down 34%, which falls well short of the return you could get by buying an index fund.
The recent uptick of 14% could be a positive sign of things to come, so let's take a look at historical fundamentals.
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
In the last half decade JETEMA saw its share price fall as its EPS declined below zero. At present it's hard to make valid comparisons between EPS and the share price. However, we can say we'd expect to see a falling share price in this scenario.
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
It might be well worthwhile taking a look at our free report on JETEMA's earnings, revenue and cash flow.
A Different Perspective
While the broader market gained around 68% in the last year, JETEMA shareholders lost 9.1%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for JETEMA you should know about.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on South Korean exchanges.
Mobile Infrastructure for Defense and Disaster
The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.
Get the investor briefing before the next round of contracts
Sponsored On Behalf of CiTechNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A216080
JETEMA
A bio venture company, engages in the research and development of medicines and medical devices.
Slightly overvalued with minimal risk.
Market Insights
Weekly Picks
Early mover in a fast growing industry. Likely to experience share price volatility as they scale

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08
Recently Updated Narratives
Airbnb Stock: Platform Growth in a World of Saturation and Scrutiny
Adobe Stock: AI-Fueled ARR Growth Pushes Guidance Higher, But Cost Pressures Loom
Thomson Reuters Stock: When Legal Intelligence Becomes Mission-Critical Infrastructure
Popular Narratives

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

The AI Infrastructure Giant Grows Into Its Valuation
Trending Discussion
